This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ViroPharma Presents New Cinryze® (C1 Esterase Inhibitor [human]) Data On Site Of Care And Adherence At The 2012 Academy Of Managed Care Pharmacy Educational Conference

Stocks in this article: VPHM





EXTON, Pa., Oct. 4, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced the results from an analysis of a patient-database involving Cinryze ® (C1 esterase inhibitor [human]) demonstrating that ViroPharma's Path to Independence™ program, a self-administration training and support program for hereditary angioedema (HAE) patients receiving prophylactic Cinryze, positively impacts the site of care in favor of home/self-administration as well as adherence to routine preventive therapy. These findings were presented at the Academy of Managed Care Pharmacy (AMCP) Educational Conference in Cincinnati.

A similar analysis of this patient-database of 516 patients to assess the site of care was first conducted in June 2010. Six months later, ViroPharma's Path to Independence training and support program was implemented to educate eligible patients on self-administration of Cinryze. In early 2012, patient-reported demographic data from this Cinryze database of 789 HAE patients were examined. These results were compared to the 2010 analysis and reflect distributions of site of care for similar lengths of time before and after the initiation of the training and support program.

The site of care for patients receiving Cinryze (N=789) was 75.8 percent at home, 16.1 percent at an infusion center, and 8.1 percent at a physician's office, compared to 47.1, 23.3, and 27.5 percent, respectively, from the 2010 analysis.  Of the 75.8 percent patients who infused at home, 57.9 percent self-administered, 26.6 percent were infused by a home health agency nurse, 14.7 percent by a family member, and 0.8 percent by other. Overall, self-administration was reported in 43.7 percent of patients compared to 20.0 percent from the 2010 analysis. Patients required an average of 5 visits to be successfully trained. Discontinuation rates of trained patients were 5 percent compared to 10 percent for untrained patients suggesting that non-program patients were twice as likely to stop therapy.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs